Bilgic, A.; Kodjikian, L.; Srivastava, S.; Dwivedi, S.; Banker, A.S.; Abukashabah, A.; Sudhalkar, A.; Mathis, T.
Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study. J. Clin. Med. 2021, 10, 4153.
https://doi.org/10.3390/jcm10184153
AMA Style
Bilgic A, Kodjikian L, Srivastava S, Dwivedi S, Banker AS, Abukashabah A, Sudhalkar A, Mathis T.
Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study. Journal of Clinical Medicine. 2021; 10(18):4153.
https://doi.org/10.3390/jcm10184153
Chicago/Turabian Style
Bilgic, Alper, Laurent Kodjikian, Samaresh Srivastava, Shyamal Dwivedi, Alay S Banker, Amro Abukashabah, Aditya Sudhalkar, and Thibaud Mathis.
2021. "Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study" Journal of Clinical Medicine 10, no. 18: 4153.
https://doi.org/10.3390/jcm10184153
APA Style
Bilgic, A., Kodjikian, L., Srivastava, S., Dwivedi, S., Banker, A. S., Abukashabah, A., Sudhalkar, A., & Mathis, T.
(2021). Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study. Journal of Clinical Medicine, 10(18), 4153.
https://doi.org/10.3390/jcm10184153